Search
Mitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigationalMitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_. … [A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper
Categories: Compounds used in a research, industrial, or household settingVoretigene neparvovec
go.drugbank.com/drugs/DB13932ApprovedInvestigationalVoretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy.[L1094] An adeno-associated virus is a small virus that infects humans and other primates. … [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095]
Synonyms: VN-rzylFlutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalIt is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029] … Flutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density.
Categories: Compounds used in a research, industrial, or household settingSodium tartrate
go.drugbank.com/drugs/DB13707ApprovedWithdrawnIt acts as an emulsifier and pH control agent in food products [L2590]. … This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% concentration, according to Health Canada regulations [L2594].
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigational[A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive … therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalin MS therapy. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Migalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigationalThis enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … [L47036,L47057,L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated
Methadyl acetate
go.drugbank.com/drugs/DB01433ExperimentalIllicitIt is used mainly in the treatment of narcotic dependence.
Rifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawn[L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid.
Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance … [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]
Synonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-